MHF Religious War

[TheReal_ND]

You should quit now and send it all to me. It's too expensive a hobby for you.

[Fife]

What's your favorite flavor of CBD juice?

Banana Hammock Blues or John Redcorn StraightArrow?

[Speaker to Animals]

Hippies

[Fife]

Or how about some Esketamine Rainbow?

[TheReal_ND]

Holy shit these pharma jews are out of control lol

[Fife]

Coming soon to the vaping tubes at the cis-male desks at a government elementary school near you.





Yeah, you all are probably right, we should just try to fix the Department of Education. With a few tweaks it will be just fine.

[Fife]

The approval is a significant milestone. Depression is the world's leading cause of poor health and disability, and as many as one in three patients don't get relief from existing antidepressants. For several decades, psychiatrists and other mental-health researchers have expressed optimism about positive findings related to ketamine, esketamine's chemical cousin. One group even called the drug "the most important discovery in half a century."

lel, pass that shit around dog

[Fife]

The list price of the new drug ranges from $590 to $885 per treatment session, depending on the dose a patient needs, Johnson & Johnson said. In the first month of treatment, patients undergo two sessions a week at a total price of roughly $5,000 to $7,000. In the second month, patients are treated weekly or once every two weeks, which helps lower the price to about $2,300 to $3,500 a month. The actual amount that patients end up paying will depend on how health insurers decide to cover the treatment.

The approval comes on the heels of a favorable vote last month from a panel of experts convened by the FDA who concluded that the drug was safe and effective. They also said they believed esketamine's benefits outweighed its risks. Still, the experts said esketamine has some important negative side effects and limitations.

Fuck it dog, hit me again

[Fife]

BASED TIFFANY APPROVES

"There has been a long-standing need for additional effective treatments for treatment-resistant depression, a serious and life-threatening condition," Tiffany Farchione, the FDA's acting director in the division of psychiatry products, said in a statement.

And upon careful review, they felt Johnson & Johnson's new drug met the criteria to become one of those treatments, Farchione added.

[Fife]

(((Steven))) says just relax bro . . . time for a game changer on this bitch.

"I think there's substantial evidence that this could be a game-changer," Steven Meisel, a system director of medication safety with Fairview Health Services and a member of last month's panel, said after reviewing the data from Johnson & Johnson's five clinical trials.